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Over the past 20 years the total number of breast cancer
diagnoses per year in the UK has risen from about 25,000 to
44,000. Although many of the affected women have a very
good prognosis, the diagnosis for each is one of the most
distressing experiences of their life. For almost all women, the
frequently persistent psychological morbidity will be
accompanied by need for surgery, radiotherapy and some
form of adjuvant medical treatment. Thus, although it is
gratifying to note the approximately 25% decrease in breast
cancer mortality over the same period, the goal of reducing
breast cancer risk is as important as ever.
A number of risk reduction strategies are available that vary in
terms of the level of evidence for their effectiveness and in
their impact on quality of life. The characterization of individual
risk is essential for a judgement to be made by a woman and
her health care professional regarding the value to be gained
by any risk reduction and the intervention that might be
appropriate for her. The short communications included in this
section of the supplement deal individually with most of the
opportunities for estimating risk and consider the likely value
of incorporating these into an integrated multifactorial
approach. Finally, the psychological factors that govern the
best way to present this information are considered.
Hormonal factors
The well established association of breast cancer risk with
several readily recordable reproductive factors, such as
parity, age at first full-term pregnancy and age of menopause,
makes them attractive candidates for inclusion in any multi-
factorial risk algorithm. Over recent years prospective studies
of plasma hormone levels in relation to breast cancer occur-
rence have revealed that higher plasma oestrogen and
androgen levels and lower sex hormone binding globulin
levels correlate with increased breast cancer risk in post-
menopausal women. It is widely accepted that the mecha-
nism underlying this is, at least in part, the mitogenic effect of
the oestrogens on oestrogen receptor positive cells of
normal, transforming and frankly malignant breast epithelial
cells. There is unresolved controversy about whether direct
carcinogenic effects of some oestrogen metabolites, which
can clearly be demonstrated in model systems, also have a
significant impact in women. Although this is largely
unimportant in the potential use of plasma hormone levels for
risk estimation, it would be a significant factor in selection of
chemopreventive strategy, because oestrogen deprivation
(for instance, aromatase inhibitors) would be expected to
inhibit such an effect whereas oestrogen antagonists (for
instance, tamoxifen) would not.
At present, despite its theoretical justification, measurement
of plasma hormones has not been incorporated into risk
algorithms. This is partly because of the paucity of well
proven standardized assays for use in postmenopausal
women and the need for application of such assays in very
large sample sets. Such studies are needed to determine the
interaction and independent significance of the hormone
measurements alongside other more easily measured factors
such as body mass index (BMI), which is correlated with
plasma oestrogen levels in postmenopausal women as well
as being a risk factor itself.
Lifestyle
There is persuasive epidemiological evidence that certain
lifestyle factors, in addition to those associated with
reproduction, are related to increased breast cancer risk. The
majority of these factors relate to diet, with an emphasis on
fat and overall calorific content. A clear characterization of
risk determinants is not available because of the difficulty
associated with quantifying dietary components and because
the presence of one component in a diet is generally
counterbalanced by the presence of another, making it
impossible to ascribe risk confidently to an individual factor.
BMI, weight and weight gain may partly represent, and be
useful as, an integrative measure of such dietary lifestyle, and
they are much more amenable to measurement.
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The evidence that modifications to lifestyle have a significant
effect in reducing breast cancer risk is also modest. Although
the modifications such as reduced calories, and increased
fruit and reduced fat consumption are those that would
generally be considered to be helpful to general health,
contemporary population behaviour has led to a worrying
obesity epidemic, despite the evidence for this being a health
risk. This suggests that there is a need for very clear evidence
that risk reduction may result from lifestyle changes that have
a significant effect on individual behaviour patterns.
Genetics
Over recent years a small number of highly penetrant genes,
such as TP53 and BRCA1/BRCA2, have been discovered
that profoundly increase the risk for breast cancer. The
identification of strong pedigrees of breast cancer (with or
without other cancer types) often leads to a search for
causation by sequencing these genes. The demonstration of
such a genetic aberration in a family and individuals therein
can substantially alter personal risk to the extent that it makes
consideration of other factors redundant. It is now widely
accepted that it is highly unlikely that further genes of this
type remain to be discovered. More recently, several
moderate and many low penetrance genes have been
identified (through genome-wide association studies); thus
far, the indication is that incorporation of these only has slight
effect on established risk profile algorithms. It is possible that
the identification of more moderate/low penetrance genes
may be discovered by research conducted within groups of
breast cancers that are defined by phenotypic histopatho-
logical and/or molecular features (for example, oestrogen
receptor positive or negative; lobular versus ductal).
Integration of risk factors
The possible integration of individual factors into risk algorithms
is discussed in each of the sections above. Mammographic
density is the most important factor that is not covered above,
and this measure is readily available in the large majority of
middle-aged women by virtue of their attendance at screening
clinics. It may also be feasible to incorporate certain of the
other factors, but to derive a tool that has sufficient certainty to
have wide applicability will require comprehensive assessment
of all potential factors in studies of many tens of thousands of
women. Ideally, this work would be done within the UK National
Health Service screening programme, such that it would be
immediately transferable to that context and allow discussion of
both breast cancer risk and possible interventions. This
concept is widely recognized but progress in implementation is
slow. In terms of the possible focusing of screening activity in
those at greatest risk, it is disappointing to note that so far only
about 5% of women can be identified as having less than 50%
average risk.
Psychosocial aspects
The delivery of risk estimates to individuals is complicated by
the degree of accuracy in public perception that risk is very
variable. Of the strategies to communicate risk, diagrammatic
representation has proven to be particularly helpful. It is of
particular note that the framing of information can profoundly
affect perception of risk. Although this fact may provide an
opportunity to improve optimal clinical trial recruitment, it also
imposes an ethical imperative upon the clinician to present
data in such a way as to elicit the most accurate
interpretation. A challenge for recruitment to trials of
prevention remains achievement of greater acceptance by
women at highest risk of intensive/invasive intervention, but
also to address their lesser willingness to be randomized to
markedly different strategies.
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